Surmodics, Inc.
SRDX · NASDAQ
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Market Cap | $549 | $450 | $423 | $765 |
| - Cash | $36 | $41 | $19 | $31 |
| + Debt | $33 | $33 | $15 | $14 |
| Enterprise Value | $546 | $442 | $419 | $748 |
| Revenue | $126 | $133 | $100 | $105 |
| % Growth | -4.9% | 32.6% | -4.9% | – |
| Gross Profit | $93 | $61 | $29 | $41 |
| % Margin | 73.8% | 46% | 29% | 39.2% |
| EBITDA | $5 | $15 | -$12 | $15 |
| % Margin | 3.8% | 11.4% | -12.2% | 14% |
| Net Income | -$12 | -$2 | -$27 | $4 |
| % Margin | -9.2% | -1.2% | -27.3% | 4% |
| EPS Diluted | -0.82 | -0.11 | -1.96 | 0.3 |
| % Growth | -645.5% | 94.4% | -753.3% | – |
| Operating Cash Flow | $0 | $11 | -$17 | $15 |
| Capital Expenditures | -$3 | -$3 | -$3 | -$6 |
| Free Cash Flow | -$3 | $8 | -$21 | $9 |